ADVERTISEMENTs

Kashiv BioSciences names Sandeep Nilkanth Athalye as CEO

Athalye will lead Kashiv BioSciences' global growth, focusing on biosimilars innovation and strategic market expansion.

Sandeep Athalye. / Image - LinkedIn/ Sandeep Athalye

New Jersey-based global biopharmaceutical company, Kashiv BioSciences, has appointed Sandeep Nilkanth Athalye as its global chief executive officer (CEO), the company announced. 

Athalye, a veteran with more than 20 years of experience in the pharmaceutical industry, will lead Kashiv’s operations and strategic expansion across the United States, Europe, and Asia, a release stated.

He joins Kashiv from Biocon Biologics, prior to which he held leadership roles at major industry players, including Boehringer Ingelheim, Novartis, and Schering-Plough Research Institute. Known for his commitment to patient-centered innovation, he brings a wealth of expertise in clinical development, regulatory strategy, and research and development.

“Kashiv has a clear objective to be among the top biosimilars players with a differentiated pipeline and state-of-the-art manufacturing and R&D facilities in the U.S. and India. I am very excited for the opportunity to use technology and innovation to drive Kashiv to become one of the leading developers of medicines in the biologics space,” Athalye said. 

The appointment comes as Kashiv BioSciences, co-founded by Indian Americans Chirag and Chintu Patel, aims to bolster growth in the rapidly expanding biosimilars sector. “We are confident that Dr. Athalye’s industry expertise and leadership will be instrumental in achieving Kashiv’s ambitious global vision,” the co-founders said.

Athalye holds an MBBS in Medicine from Bharati Vidyapeeth in India, an MS in Clinical Pharmacology from the University of Toledo, and an MBA in BioPharma Innovation from Rutgers University.
 

Comments

ADVERTISEMENT

 

 

 

ADVERTISEMENT

 

 

E Paper